KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Equity Income (2016 - 2025)

West Pharmaceutical Services' Equity Income history spans 17 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Equity Income rose 95.0% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $14.4 million, down 2.04%, while the annual FY2025 figure was $14.4 million, 2.04% down from the prior year.
  • Equity Income for Q4 2025 was $3.9 million at West Pharmaceutical Services, up from $2.1 million in the prior quarter.
  • Across five years, Equity Income topped out at $8.6 million in Q2 2021 and bottomed at $2.0 million in Q4 2024.
  • The 5-year median for Equity Income is $4.5 million (2024), against an average of $4.6 million.
  • The largest YoY upside for Equity Income was 95.0% in 2025 against a maximum downside of 46.15% in 2025.
  • A 5-year view of Equity Income shows it stood at $6.5 million in 2021, then plummeted by 50.77% to $3.2 million in 2022, then grew by 3.12% to $3.3 million in 2023, then plummeted by 39.39% to $2.0 million in 2024, then soared by 95.0% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Equity Income are $3.9 million (Q4 2025), $2.1 million (Q3 2025), and $5.0 million (Q2 2025).